BALTIMORE, Oct. 26 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. , a company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an agreement with Ortho Biotech Oncology Research & Development, a Division of Janssen Pharmaceutica NV, for the evaluation of a novel preclinical oncology therapeutic in Champions’ Biomerk Tumorgraft(TM) platform.
For more information regarding Champions Biotechnology’s growing business and recent news, please visit www.championsbiotechnology.com.
www.championsbiotechnology.com
www.personalizedcancertreatment.com
CONTACT: James Carbonara, The Investor Relations Group, Inc.,
+1-212-825-3210
Web site: http://championsbiotechnology.com/
